A
Agenus Inc. (AGEN)
NCM – Real vaqt narxi. Valyuta: USD
3.44
+0.18 (5.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
3.44
+0.18 (5.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Agenus Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlar va xalqaro miqyosda saraton va yuqumli kasalliklar uchun immunoterapiyalarni kashf etadi va ishlab chiqadi. U to'liq inson va insonlashtirilgan monoklonal antitelarni aniqlash uchun antitel ifodalash platformasi Retrocyte Display va displey texnologiyalarini taklif etadi. U QS-21 Stimulon adjuvantini, saponin asosidagi vaksina adjuvantini ishlab chiqadi. Kompaniya shuningdek, Balstilimab, o'lim retseptorining-1 (PD-1) blokirovka qiluvchi antitelini; AGEN1181, metastatik kolorektal saraton (mCRC), oshqozon osti bezi saratoni va melanomada 2-bosqich sinovlarida bo'lgan inson Fc bilan kuchaytirilgan sitotoksik T-limfotsit antigeni 4 (CTLA-4) blokirovka qiluvchi antitelini; AGEN2373, 1b-bosqichli klinik sinovda bo'lgan CD137 monospesifik antitelini; AGEN1423, CD73/TGFβ TRAP antitelini; AGEN1571, klinik rivojlanishda bo'lgan ILT2 monospesifik antitelini; va BMS-986442, TIGIT bispesifik antitelini ishlab chiqadi. Bundan tashqari, u INCAGN1876, GITR agonisti; INCAGN2390, TIM-3 monoklonal antitelari; INCAGN2385, LAG-3 monospesifik antitelini; MK-4830, 2-bosqichli klinik sinovda bo'lgan ILT4 ni maqsad qilib olgan monospesifik antitelini; va AGEN1884 ni ishlab chiqadi. Kompaniya Agenus, MiNK, Prophage, Retrocyte Display va STIMULON savdo belgilari ostida faoliyat yuritadi. U Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation va Merck Sharp & Dohme bilan hamkorlik qiladi. Kompaniya ilgari Antigenics Inc. nomi bilan tanilgan va 2011-yil yanvar oyida Agenus Inc. nomini o'zgartirgan. Agenus Inc. 1994-yilda tashkil etilgan va shtab-kvartirasi Massachusets shtatining Lexington shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Craig Winter | Chief Information Officer |
| Dr. Garo H. Armen Ph.D. | Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman |
| Dr. Jennifer S. Buell Ph.D. | Director and President & CEO of MiNK Therapeutics |
| Dr. Robin G. Taylor M.B.A., Ph.D. | Chief Commercial Officer |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer |
| Dr. Todd Jude Yancey M.D. | Member of Advisory Board & Chief Strategic Advisor |
| Mr. Austin Charette | Senior Director, Financial Reporting and Compliance & Principal Accounting Officer |
| Mr. Zack Armen | Vice President of Investor Relations & Corporate Development |
| Ms. Stefanie Perna-Nacar | Chief Communications & Government Relations Officer |
| Ms. Tracy Mazza Clemente | Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEF 14A | agen-20260430.htm |
| 2026-04-20 | PRE 14A | agen-20260420.htm |
| 2026-03-26 | 8-K | agen-20260324.htm |
| 2026-03-16 | 10-K | agen-20251231.htm |
| 2026-01-16 | 8-K | agen-20260115.htm |
| 2026-01-14 | 8-K | agen-20260108.htm |
| 2026-01-08 | 8-K | agen-20260103.htm |
| 2025-12-29 | S-3ASR | d789323ds3asr.htm |
| 2025-11-10 | 10-Q | agen-20250930.htm |
| 2025-10-09 | 8-K | agen-20251008.htm |